Lercanidipina Gp

Lercanidipine, the active ingredient in Lercanidipina Gp, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle. The medication belongs to the dihydropyridine subclass and is marketed within the European Union.

GNH USA supplies Lercanidipina Gp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker used primarily in the treatment of hypertension.

- Hypertension: lowers elevated blood pressure in adults with primary hypertension. - Essential hypertension: provides sustained blood pressure control in patients with essential hypertension. - Isolated systolic hypertension: helps reduce systolic pressure in patients with isolated systolic hypertension.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dose initiation. - Flushing: sensation of warmth and redness, especially on the face and neck. - Peripheral edema: swelling of the ankles or lower legs due to fluid accumulation. - Dizziness: light‑headed feeling, often related to blood pressure changes. - Fatigue: general tiredness without a clear cause.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease. - Hepatic dysfunction: abnormal liver enzyme elevations indicating possible liver injury. - Allergic reactions: rash, pruritus, or anaphylaxis requiring immediate medical attention.

Before initiating therapy with Lercanidipine, several safety considerations should be observed. - Blood pressure monitoring: measure baseline and periodic blood pressure to assess efficacy and avoid excessive drops. - Renal impairment: use cautiously in patients with severe renal dysfunction; adjust monitoring frequency. - Hepatic impairment: consider dose adjustment or close observation in moderate to severe liver disease. - Concomitant antihypertensives: avoid excessive hypotension when combined with other blood‑pressure‑lowering agents. - Pregnancy and lactation: safety not established; avoid unless clearly indicated. - Store at room temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes, influencing its safety and effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and precipitate hypotension. - Grapefruit juice: can raise drug levels, enhancing the risk of adverse effects. - Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate antihypertensive effect; monitor blood pressure and electrolytes. - Beta‑blockers: combined effect on heart rate; watch for bradycardia. - ACE inhibitors or ARBs: additive blood‑pressure reduction; adjust therapy as needed.